COEP News & Events

Coeptis Therapeutics announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". The new listing is expected to become effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly owned subsidiary of Coeptis and the Company will change its corporate name to Z Squared Inc. The new listing application approval follows the satisfaction of other key closing conditions to the proposed merger, including effectiveness of the Company's registration statement on Form S-4 and shareholder approval of the merger proposals at the Company's January 30, 2026 stockholders' meeting. In connection with the consummation of the business combination, Z Squared will become a wholly owned subsidiary of Coeptis, and the Company will change its corporate name to Z Squared Inc. The transaction remains subject to satisfaction of any remaining customary closing conditions, and there can be no assurance that such conditions will be satisfied. The transaction is expected to close in Q2 2026.

Coeptis Therapeutics Holdings announced that its registration statement on Form S-4, relating to the previously announced merger transaction with Z Squared, has been declared effective by the U.S. Securities and Exchange Commission and that it will commence mailing the definitive proxy statement/prospectus relating to the Annual/Special Meeting of the Company's stockholders to be held on January 30, 2026, in connection with the Transaction. The proxy statement/prospectus is being mailed to the Company's stockholders of record as of the close of business on January 2, 2026. Notice of the Stockholder Meeting will be mailed on or about January 7, 2026 to stockholders of record as of the Record Date. While the combined company has submitted an application to list the combined company's common stock on The Nasdaq Stock Market, approval has not yet been obtained and there can be no assurance that such listing application will be approved or that the combined company will meet the applicable listing standards. If the combined company is unable to obtain listing on a national securities exchange, the combined company's securities will continue to trade on the OTC Markets following the Transaction.

Coeptis Therapeutics announced the extinguishment of its convertible note with YA II PN. The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company's outstanding debt obligations to Yorkville.

Coeptis Therapeutics announced the filing of a registration statement on Form S-4 with the Securities and Exchange Commission related to the Company's previously announced and proposed definitive merger agreement with Z Squared. The Form S-4 includes a preliminary proxy statement/prospectus regarding the proposed transaction. The registration statement has not yet become effective, and the information contained therein is subject to change.